Moderna Announces Phase 1/2 Data From mRNA-1083, Combination Vaccine Against Influenza, COVID-19, Showing Strong Immunogenicity And Acceptable Reactogenicity And Safety Profile Compared To Standalone Vaccines
Portfolio Pulse from Benzinga Newsdesk
Moderna has announced Phase 1/2 data from mRNA-1083, a combination vaccine against Influenza and COVID-19. The results show strong immunogenicity and an acceptable reactogenicity and safety profile compared to standalone vaccines.
October 04, 2023 | 11:11 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna's mRNA-1083 vaccine shows promising Phase 1/2 data, potentially boosting the company's vaccine portfolio and market position.
The positive Phase 1/2 data for Moderna's mRNA-1083 vaccine could potentially enhance the company's reputation and market position in the vaccine industry. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100